Pipelines

Anti IPD

Discovery

Early

Late

Pre-clinical

Early

Late

Clinical-trial

Phase 1

Phase 2

Phase 3

Marketing

authorization

ON GOING

Pneumococcal 13

Pneumococcal 20+

Anti IMD

Discovery

Early

Late

Pre-clinical

Early

Late

Clinical-trial

Phase 1

Phase 2

Phase 3

Marketing

authorization

ON GOING

Meningococcal Group ACWY

Meningococcal Group B L8 Endotoxoid (Concept for Safety Phase I)

Meningococcal Group B L7 Endotoxoid
(Nanostructured VS)

Meningococcal Pentavalent (A,B,C,W,Y)

Multidrug Resistance

Discovery

Early

Late

Pre-clinical

Early

Late

Clinical-trial

Phase 1

Phase 2

Phase 3

Marketing

authorization

Clostridium Difficile

- Escherichia
- Coli
- Salmonella
- Typhi

- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Acinetobacter baumannii

Nanostructured Vector System for Viral subunit vaccines

Discovery

Early

Late

Pre-clinical

Early

Late

Clinical-trial

Phase 1

Phase 2

Phase 3

Marketing

authorization

- COV-2
- RSV
- Influenza